155 related articles for article (PubMed ID: 24784346)
1. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Coosemans A; Vergote I; Van Gool SW
Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno S; Kyo S; Myojo S; Dohi S; Ishizaki J; Miyamoto K; Morita S; Sakamoto J; Enomoto T; Kimura T; Oka Y; Tsuboi A; Sugiyama H; Inoue M
Anticancer Res; 2009 Nov; 29(11):4779-84. PubMed ID: 20032435
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
Sugiyama H
Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
[TBL] [Abstract][Full Text] [Related]
4. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
Sugiyama H
Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
[TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
6. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
7. Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman ZN; Vergote I; Amant F; VAN Gool SW
Anticancer Res; 2013 Dec; 33(12):5495-500. PubMed ID: 24324087
[TBL] [Abstract][Full Text] [Related]
8. Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Ohno S; Takano F; Ohta Y; Kyo S; Myojo S; Dohi S; Sugiyama H; Ohta T; Inoue M
Anticancer Res; 2011 Jul; 31(7):2447-52. PubMed ID: 21873158
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy targeting WT1 protein.
Sugiyama H
Int J Hematol; 2002 Aug; 76(2):127-32. PubMed ID: 12215010
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
Koido S; Okamoto M; Shimodaira S; Sugiyama H
Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
[TBL] [Abstract][Full Text] [Related]
11. HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system.
Kanda T; Ochi T; Fujiwara H; Yasukawa M; Okamoto S; Mineno J; Kuzushima K; Tsurumi T
Cancer Gene Ther; 2012 Aug; 19(8):566-71. PubMed ID: 22722376
[TBL] [Abstract][Full Text] [Related]
12. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
Van Driessche A; Berneman ZN; Van Tendeloo VF
Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
[TBL] [Abstract][Full Text] [Related]
13. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
14. Wilms' tumor 1 (WT1) as a prognosis factor in gynecological cancers: A meta-analysis.
Lu J; Gu Y; Li Q; Zhong H; Wang X; Zheng Z; Hu W; Wen L
Medicine (Baltimore); 2018 Jul; 97(28):e11485. PubMed ID: 29995811
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy.
Schillingmann DA; Riese SB; Vijayan V; Tischer-Zimmermann S; Schmetzer H; Maecker-Kolhoff B; Blasczyk R; Immenschuh S; Eiz-Vesper B
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678050
[TBL] [Abstract][Full Text] [Related]
16. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A; Oka Y; Osaki T; Kumagai T; Tachibana I; Hayashi S; Murakami M; Nakajima H; Elisseeva OA; Fei W; Masuda T; Yasukawa M; Oji Y; Kawakami M; Hosen N; Ikegame K; Yoshihara S; Udaka K; Nakatsuka S; Aozasa K; Kawase I; Sugiyama H
Microbiol Immunol; 2004; 48(3):175-84. PubMed ID: 15031530
[TBL] [Abstract][Full Text] [Related]
17. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.
Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman Z; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2013 Sep; 33(9):3855-9. PubMed ID: 24023319
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
19. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
[TBL] [Abstract][Full Text] [Related]
20. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
